黄芪桂枝五物汤联合隔物灸治疗非小细胞肺癌的疗效及对患者T淋巴细胞功能的影响

doi:10.3969/j.issn.1671-7171.2025.04.029

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1213 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the efficacy of Huangqi Guizhi Wuwu Decoction combined with indirect moxibustion and its impact on T lymphocyte function in the treatment of patients non-small cell lung cancer (NSCLC).【Methods】A total of 106 patients with NSCLC were randomly divided into the control group and the observation group, with 53 patients in each group. The control group received conventional treatment, while the observation group was treated with Huangqi Guizhi Wuwu Decoction combined with indirect moxibustion on top of the conventional treatment. The efficacy, T lymphocyte function before and after treatment, traditional Chinese medicine syndrome scores, KPS scores, vascular endothelial growth factor (VEGF) levels, and the incidence of adverse reactions were compared between the two groups.【Results】 After treatment, the total effective rate in the observation group was higher than that in the control group (P<0.05). The observation group had significantly higher levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ ratios, and lower CD8⁺ level compared to the control group (P<0.05). The TCM syndrome scores and VEGF level in the observation group were lower than those in the control group, while the KPS score in the observation group was higher than that in the control group (P<0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05).【Conclusion】Huangqi Guizhi Wuwu Decoction combined with indirect moxibustion significantly improves the efficacy of treatment and T lymphocyte function in NSCLC patients, alleviates traditional Chinese medicine syndrome scores, enhances KPS score, reduces VEGF level, and lowers the incidence of adverse reactions.

Key words： Carcinoma Non-Small-Cell Lung Huangqi Guizhi Decoction T-Lymphocytes Treatment Outcome

Received: 31 August 2024

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GU Aili
	ZHAO Ling
	TANG Zhimin
	et al

Cite this article:

GU Aili,ZHAO Ling,TANG Zhimin, et al. Efficacy of Huangqi Guizhi Wuwu Decoction Combined with Indirect Moxibustion and its Effect on T Lymphocyte Function in Treatment of Patients with Non-Small Cell Lung Cancer in Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(4): 663-665.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.04.029 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I4/663

[1] 王居巳,宋伟安,狄守印,等. 新辅助化疗联合免疫抑制剂对Ⅲ期非小细胞肺癌治疗有效性分析[J].首都医科大学学报,2024,45(4):660-665.
[2] 朱志朋,虞淦军,许炜. 地舒单抗联合免疫检查点抑制剂在非小细胞肺癌骨转移中的临床研究进展[J].中国肿瘤生物治疗杂志,2024,31(5):528-534.
[3] 李萱,潘华,张晓鹏,等. 达克替尼联合西妥昔单抗治疗晚期非小细胞肺癌的临床疗效及生存情况分析[J].医学临床研究,2024,41(3):420-423.
[4] 郭海丽. 黄芪桂枝五物汤熏洗联合艾灸治疗奥沙利铂所致恶性肿瘤患者周围神经毒性的临床疗效[J].浙江中医药大学学报,2021,45(5):521-525.
[5] 王清溪,杜桢,于小盼. 隔物灸治疗肺癌患者NP方案化疗后脾肾阳虚型白细胞减少症的疗效探析[J].哈尔滨医药,2020,40(6):586-587.
[6] 张渊,周珂玮,王邦才. 桃红四物汤合三子养亲汤加减治疗气滞血瘀型晚期非小细胞肺癌咳喘临床研究[J].新中医,2021,53(8):103-106.
[7] 吴丽明,金鹿,马继明,等. 华蟾素胶囊、依托泊苷联合顺铂治疗老年非小细胞肺癌对患者炎症因子、血清肿瘤标志物的影响[J].海南医学,2020,31(1):20-23.
[8] 阎丽,严亚军. 非小细胞肺癌患者血清IGF-1、IL-1α水平与新辅助化疗临床疗效的关系[J].医学临床研究,2023,40(10):1529-1532.
[9] 李卓,乔玲,王艺洁,等. 中医扶正解毒法治疗晚期非小细胞肺癌的Meta分析[J].中国药房,2024,35(13):1651-1657.
[10] 郭婷婷,张国铎,胡陵静,等. 健脾益肺散结方联合隔物灸治疗晚期非小细胞肺癌临床观察[J].辽宁中医药大学学报,2022,24(9):88-91.
[11] 陈云容,周晋华. 加味黄芪桂枝五物汤联合TP方案在非小细胞肺癌治疗中的临床观察[J].云南中医中药杂志,2023,44(4):42-44.
[12] 陆丹红,许坚. 隔物灸联合阿瑞匹坦及昂丹司琼对晚期肺癌含顺铂方案化疗所致恶心呕吐的预防效果研究[J].陕西中医,2020,41(8):1084-1087.
[13] 陈涛利,柳云飞,王延朋,等. 恩度联合埃克替尼对晚期非小细胞肺癌患者化疗敏感性、肿瘤标志物及预后的影响[J].中国医科大学学报,2024,53(7):610-615.